开云app官网登录入口网页版-官方正版

#II期临床试验#

174篇内容 | 2467人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1931572, encodeId=d96519315e242, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=乐复能治疗重症新冠肺炎III期临床试验数据公布，降低重症病人的呼吸衰竭和死亡率58.3%, objectType=article, longId=219794, objectId=be3b219e94bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be3b219e94bc, replyNumber=0, likeNumber=81, createdTime=2021-11-15, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be3b219e94bc, moduleTitle=乐复能治疗重症新冠肺炎III期临床试验数据公布，降低重症病人的呼吸衰竭和死亡率58.3%, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=be3b219e94bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931569, encodeId=da8619315695a, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=靶向IL-4R单克隆抗体 (AK120) 治疗特应性皮炎和哮喘，中国II期临床试验已经启动, objectType=article, longId=218737, objectId=eb23218e37f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb23218e37f3, replyNumber=0, likeNumber=113, createdTime=2021-11-10, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb23218e37f3, moduleTitle=靶向IL-4R单克隆抗体 (AK120) 治疗特应性皮炎和哮喘，中国II期临床试验已经启动, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=eb23218e37f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931563, encodeId=76761931563a7, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=科济药业发布2021年中期业绩自主研发 CAR-T候选品进入海外关键II期临床试验, objectType=article, longId=216260, objectId=c3532162608a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3532162608a, replyNumber=0, likeNumber=70, createdTime=2022-06-09, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3532162608a, moduleTitle=科济药业发布2021年中期业绩自主研发 CAR-T候选品进入海外关键II期临床试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c3532162608a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931566, encodeId=70c21931566d0, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=巴西ANVISA批准Proxalutamide用于治疗住院COVID-19患者的III期临床试验, objectType=article, longId=217765, objectId=135021e76506, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=135021e76506, replyNumber=0, likeNumber=80, createdTime=2022-08-27, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=135021e76506, moduleTitle=巴西ANVISA批准Proxalutamide用于治疗住院COVID-19患者的III期临床试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=135021e76506)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931574, encodeId=a84319315e494, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=Keytruda联合PARP抑制剂III期临床试验失败！默沙东终止研究, objectType=article, longId=302280, objectId=14b430228084, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14b430228084, replyNumber=0, likeNumber=84, createdTime=2022-06-30, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14b430228084, moduleTitle=Keytruda联合PARP抑制剂III期临床试验失败！默沙东终止研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=14b430228084)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931568, encodeId=5dd419315688f, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=糖尿病创新药iGlarLixi中国III期临床试验达到主要有效性终点, objectType=article, longId=218304, objectId=0e0c218304c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e0c218304c9, replyNumber=0, likeNumber=83, createdTime=2022-08-01, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e0c218304c9, moduleTitle=糖尿病创新药iGlarLixi中国III期临床试验达到主要有效性终点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0e0c218304c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931571, encodeId=168f19315e19e, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=“吹口气测新冠”成为可能，mRNA疫苗加强针III期临床试验保护效力为95.6%丨新冠研究一周进展, objectType=article, longId=219261, objectId=3c982192618a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c982192618a, replyNumber=0, likeNumber=81, createdTime=2021-11-04, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c982192618a, moduleTitle=“吹口气测新冠”成为可能，mRNA疫苗加强针III期临床试验保护效力为95.6%丨新冠研究一周进展, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3c982192618a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931573, encodeId=b3c719315e354, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=FDA暂停了苯丙酮尿症（PKU）基因疗法BMN 307的I/II期临床试验, objectType=article, longId=299177, objectId=355f2991e79c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=355f2991e79c, replyNumber=0, likeNumber=72, createdTime=2022-06-19, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=355f2991e79c, moduleTitle=FDA暂停了苯丙酮尿症（PKU）基因疗法BMN 307的I/II期临床试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=355f2991e79c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931564, encodeId=6c97193156440, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=2021年9月12日简报：云南新增本土确诊病例7例、福建莆田市累计发现6例确诊；第二代新冠疫苗已完成II期临床试验；66岁女科学家因mRNA疫苗获大奖, objectType=article, longId=216995, objectId=8c02216995b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c02216995b9, replyNumber=0, likeNumber=64, createdTime=2022-06-23, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c02216995b9, moduleTitle=2021年9月12日简报：云南新增本土确诊病例7例、福建莆田市累计发现6例确诊；第二代新冠疫苗已完成II期临床试验；66岁女科学家因mRNA疫苗获大奖, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8c02216995b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931558, encodeId=4c041931558f8, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=FP-025治疗COVID-19相关的ARDS，II/III期临床试验已正式开始, objectType=article, longId=209159, objectId=3dc92091590c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3dc92091590c, replyNumber=0, likeNumber=72, createdTime=2021-10-05, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3dc92091590c, moduleTitle=FP-025治疗COVID-19相关的ARDS，II/III期临床试验已正式开始, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3dc92091590c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931557, encodeId=c6a3193155e73, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=ZYESAMI治疗COVID-19呼吸衰竭，IIb / III期临床试验取得积极结果, objectType=article, longId=209081, objectId=08c1209081f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08c1209081f4, replyNumber=0, likeNumber=89, createdTime=2021-07-30, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08c1209081f4, moduleTitle=ZYESAMI治疗COVID-19呼吸衰竭，IIb / III期临床试验取得积极结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=08c1209081f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931565, encodeId=c2ad19315654e, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=布美他尼用于自闭症III期临床试验失败, objectType=article, longId=217084, objectId=f94e21e084df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f94e21e084df, replyNumber=0, likeNumber=77, createdTime=2022-08-17, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f94e21e084df, moduleTitle=布美他尼用于自闭症III期临床试验失败, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f94e21e084df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931555, encodeId=c66b193155581, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=长效抗体GSK3511294控制重度哮喘，III期临床试验即将开始, objectType=article, longId=208679, objectId=00752086e9b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00752086e9b6, replyNumber=0, likeNumber=82, createdTime=2021-07-26, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00752086e9b6, moduleTitle=长效抗体GSK3511294控制重度哮喘，III期临床试验即将开始, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=00752086e9b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931570, encodeId=aca519315e0d1, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=J Clin Oncol：长春新碱-拓扑替康-环磷酰胺用于非转移性尤文氏肉瘤初始治疗的III期临床试验结果, objectType=article, longId=218769, objectId=9c2d218e69ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c2d218e69ce, replyNumber=0, likeNumber=90, createdTime=2022-06-26, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c2d218e69ce, moduleTitle=J Clin Oncol：长春新碱-拓扑替康-环磷酰胺用于非转移性尤文氏肉瘤初始治疗的III期临床试验结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9c2d218e69ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931567, encodeId=abe6193156e2a, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=Proxalutamide用于治疗美国住院COVID-19患者的III期临床试验，首次对患者给药, objectType=article, longId=218128, objectId=301e21812880, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=301e21812880, replyNumber=0, likeNumber=66, createdTime=2022-03-09, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=301e21812880, moduleTitle=Proxalutamide用于治疗美国住院COVID-19患者的III期临床试验，首次对患者给药, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=301e21812880)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931559, encodeId=372d193155982, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=康泰生物灭活新冠疫苗（KCONVAC）I/II期临床试验数据显示出优异的安全性和免疫原性, objectType=article, longId=209884, objectId=8e3c20988469, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e3c20988469, replyNumber=0, likeNumber=64, createdTime=2021-05-22, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e3c20988469, moduleTitle=康泰生物灭活新冠疫苗（KCONVAC）I/II期临床试验数据显示出优异的安全性和免疫原性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8e3c20988469)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931546, encodeId=c47119315468d, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=合成生物药物可利霉素（Carrimycin）治疗COVID-19：FDA已允许开展III期临床试验, objectType=article, longId=205036, objectId=8f5c20503649, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f5c20503649, replyNumber=0, likeNumber=80, createdTime=2021-09-09, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f5c20503649, moduleTitle=合成生物药物可利霉素（Carrimycin）治疗COVID-19：FDA已允许开展III期临床试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8f5c20503649)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931562, encodeId=069e193156213, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=Nat Med：严重肥胖和代谢综合征患者的粪便微生物移植II期临床试验 , objectType=article, longId=213880, objectId=451f213880fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=451f213880fd, replyNumber=0, likeNumber=79, createdTime=2021-12-04, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=451f213880fd, moduleTitle=Nat Med：严重肥胖和代谢综合征患者的粪便微生物移植II期临床试验 , moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=451f213880fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931561, encodeId=a298193156166, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=J Thorac Oncol: Capmatinib治疗既往应用过MET抑制剂的肺癌的疗效：一项II期临床试验, objectType=article, longId=211358, objectId=b3ef2113580f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3ef2113580f, replyNumber=0, likeNumber=70, createdTime=2021-10-29, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3ef2113580f, moduleTitle=J Thorac Oncol: Capmatinib治疗既往应用过MET抑制剂的肺癌的疗效：一项II期临床试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b3ef2113580f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931542, encodeId=0bcf19315423d, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=中国国家药品管理局批准ATG-016（Eltanexor）治疗高危骨髓增生异常综合征的I / II期临床试验, objectType=article, longId=203861, objectId=324020386153, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=324020386153, replyNumber=0, likeNumber=75, createdTime=2021-03-23, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=324020386153, moduleTitle=中国国家药品管理局批准ATG-016（Eltanexor）治疗高危骨髓增生异常综合征的I / II期临床试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=324020386153)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

II期临床试验

2020-05-29

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

乐复能治疗重症新冠肺炎III期临床试验数据公布，降低重症病人的呼吸衰竭和死亡率58.3%

2021-11-15

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

靶向IL-4R单克隆抗体 (AK120) 治疗特应性皮炎和哮喘，中国II期临床试验已经启动

2021-11-10

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

科济药业发布2021年中期业绩自主研发 CAR-T候选品进入海外关键II期临床试验

2022-06-09

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

巴西ANVISA批准Proxalutamide用于治疗住院COVID-19患者的III期临床试验

2022-08-27

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

Keytruda联合PARP抑制剂III期临床试验失败！默沙东终止研究

2022-06-30

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

糖尿病创新药iGlarLixi中国III期临床试验达到主要有效性终点

2022-08-01

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

“吹口气测新冠”成为可能，mRNA疫苗加强针III期临床试验保护效力为95.6%丨新冠研究一周进展

2021-11-04

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

FDA暂停了苯丙酮尿症（PKU）基因疗法BMN 307的I/II期临床试验

2022-06-19

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

2021年9月12日简报：云南新增本土确诊病例7例、福建莆田市累计发现6例确诊；第二代新冠疫苗已完成II期临床试验；66岁女科学家因mRNA疫苗获大奖

2022-06-23

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

FP-025治疗COVID-19相关的ARDS，II/III期临床试验已正式开始

2021-10-05

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

ZYESAMI治疗COVID-19呼吸衰竭，IIb / III期临床试验取得积极结果

2021-07-30

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

布美他尼用于自闭症III期临床试验失败

2022-08-17

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

长效抗体GSK3511294控制重度哮喘，III期临床试验即将开始

2021-07-26

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

J Clin Oncol：长春新碱-拓扑替康-环磷酰胺用于非转移性尤文氏肉瘤初始治疗的III期临床试验结果

2022-06-26

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

Proxalutamide用于治疗美国住院COVID-19患者的III期临床试验，首次对患者给药

2022-03-09

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

康泰生物灭活新冠疫苗（KCONVAC）I/II期临床试验数据显示出优异的安全性和免疫原性

2021-05-22

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

合成生物药物可利霉素（Carrimycin）治疗COVID-19：FDA已允许开展III期临床试验

2021-09-09

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

Nat Med：严重肥胖和代谢综合征患者的粪便微生物移植II期临床试验

2021-12-04

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

J Thorac Oncol: Capmatinib治疗既往应用过MET抑制剂的肺癌的疗效：一项II期临床试验

2021-10-29

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

中国国家药品管理局批准ATG-016（Eltanexor）治疗高危骨髓增生异常综合征的I / II期临床试验

2021-03-23

科室
- - 订阅+
  - 更多科室
工具
服务